@article{WOS:000470964100043,
 abstract = {Although previous research identified candidate genetic polymorphisms
associated with cisplatin nephrotoxicity, varying outcome definitions
potentially contributed to the variability in the effect size and
direction of this relationship. We selected genetic variants that have
been significantly associated with cisplatin-induced nephrotoxicity in
more than one published study (SLC22A2 rs316019; ERCC1 rs11615 and
rs3212986; ERCC2 rs1799793 and rs13181) and performed a replication
analysis to confirm associations between these genetic polymorphisms and
cisplatin nephrotoxicity using various outcome definitions. We included
282 germ cell testicular cancer patients treated with cisplatin from
2009-2014, aged >17 years recruited by the Canadian Pharmacogenomics
Network for Drug Safety. Nephrotoxicity was defined using four grading
tools: (1) Common Terminology Criteria for Adverse Events (CTCAE) v4.03
for acute kidney injury (AKI) or CTCAE-AKI; (2) adjusted
cisplatin-induced AKI; (3) elevation of serum creatinine; and (4)
reduction in the estimated glomerular filtration rate (eGFR).
Significant associations were only found when using the CTCAE v4.03
definition: genotype CA of the ERCC1 rs3212986 was associated with
decreased risk of cisplatin nephrotoxicity (ORadj = 0.24; 95% CI:
0.08-0.70; p = 0.009) compared to genotype CC. In contrast, addition of
allele A at SLC22A2 rs316019 was associated with increased risk (ORadj =
4.41; 95% CI: 1.96-9.88; p < 0.001) while genotype AC was associated
with a higher risk of cisplatin nephrotoxicity (ORadj = 5.06; 95% CI:
1.69-15.16; p = 0.004) compared to genotype CC. Our study showed that
different case definitions led to variability in the genetic risk
ascertainment of cisplatin nephrotoxicity. Therefore, consensus on a set
of clinically relevant outcome definitions that all such studies should
follow is needed.},
 address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
 affiliation = {Maitland-van der Zee, AH (Corresponding Author), Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Resp Med, Kruislaan 403, NL-1105 AZ Amsterdam, Netherlands.
Zazuli, Zulfan; Vijverberg, Susanne J. H.; Maitland-van der Zee, Anke H., Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Resp Med, Kruislaan 403, NL-1105 AZ Amsterdam, Netherlands.
Zazuli, Zulfan, Bandung Inst Technol, Sch Pharm, Dept Pharmacol Clin Pharm, Bandung 40132, Indonesia.
Zazuli, Zulfan; Otten, Leila S.; Masereeuw, Rosalinde, Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacol, NL-3512 JE Utrecht, Netherlands.
Drogemoller, Britt I.; Wright, Galen E. B.; Ross, Colin J. D., British Columbia Childrens Hosp Res Inst, Vancouver, BC V5Z 4H4, Canada.
Drogemoller, Britt I.; Ross, Colin J. D., Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z4, Canada.
Medeiros, Mara, Hosp Infantil Mexico Dr Federico Gomez, Nephrol Res Unit, Mexico City 06720, DF, Mexico.
Medeiros, Mara, Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Mexico City 04510, DF, Mexico.
Monzon, Jose G., Tom Baker Canc Clin, Dept Med Oncol, Calgary, AB T2N 4N2, Canada.
Wright, Galen E. B., Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada.
Kollmannsberger, Christian K.; Gelmon, Karen A., BC Canc Agcy, Vancouver, BC V6T 1Z4, Canada.
Kollmannsberger, Christian K.; Gelmon, Karen A., Univ British Columbia, Vancouver, BC V6T 1Z4, Canada.
Bedard, Philippe L., Princess Margaret Canc Ctr, Toronto, ON M5S, Canada.
Bedard, Philippe L.; Chen, Zhuo; Kitchlu, Abhijat; Liu, Geoffrey, Univ Toronto, Toronto, ON M5S, Canada.
Chen, Zhuo; Liu, Geoffrey, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med, Med Oncol & Hematol, Toronto, ON M5S, Canada.
McGoldrick, Nicole; Carleton, Bruce C., BC Childrens Hosp, Pharmaceut Outcomes Programme, Vancouver, BC V6H 3N1, Canada.
Kitchlu, Abhijat, Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON M5S, Canada.
Carleton, Bruce C., Univ British Columbia, Fac Med, Dept Pediat, Div Translat Therapeut, Vancouver, BC V6T 1Z4, Canada.},
 affiliations = {University of Amsterdam; Institute Technology of Bandung; Utrecht
University; University of British Columbia; Hospital Infantil de Mexico
Federico Gomez; Universidad Nacional Autonoma de Mexico; Tom Baker
Cancer Clinic; University of Calgary; University of British Columbia;
British Columbia Cancer Agency; University of British Columbia;
University of Toronto; University Toronto Affiliates; University Health
Network Toronto; Princess Margaret Cancer Centre; University of Toronto;
University of Toronto; University Toronto Affiliates; University Health
Network Toronto; Princess Margaret Cancer Centre; BC Childrens Hospital;
University of British Columbia; University of Toronto; University
Toronto Affiliates; University Health Network Toronto; University of
British Columbia},
 article-number = {364},
 author = {Zazuli, Zulfan and Otten, Leila S. and Drogemoller, Britt I. and
Medeiros, Mara and Monzon, Jose G. and Wright, Galen E. B. and
Kollmannsberger, Christian K. and Bedard, Philippe L. and Chen, Zhuo and
Gelmon, Karen A. and McGoldrick, Nicole and Kitchlu, Abhijat and
Vijverberg, Susanne J. H. and Masereeuw, Rosalinde and Ross, Colin J. D.
and Liu, Geoffrey and Carleton, Bruce C. and Maitland-van der Zee, Anke
H.},
 author-email = {z.zazuli@amc.uva.nl
l.s.otten@students.uu.nl
medeiro.mara@gmail.com
medeiro.mara@gmail.com
jgmonzon@ucalgary.ca
gwright@cmmt.ubc.ca
ckollmannsberger@bccancer.bc.ca
philippe.bedard@uhn.ca
Zhuo.Chen@uhnresearch.ca
kgelmon@bccancer.bc.ca
nicolemcgoldrick@hotmail.com
Abhijat.Kitchlu@uhn.ca
s.j.vijverberg@amsterdamumc.nl
R.Masereeuw@uu.nl
colin.ross@ubc.ca
Geoffrey.Liu@uhn.ca
bcarleton@popi.ubc.ca
a.h.maitland@amsterdamumc.nl},
 da = {2022-12-11},
 doc-delivery-number = {IC4VD},
 doi = {10.3390/genes10050364},
 eissn = {2073-4425},
 funding-acknowledgement = {Canadian Foundation for Innovation/Canadian Institutes of Health
Research (CIHR) [CIHR CRI-88362]; CIHR-Drug Safety and Effectiveness
Network [CIHR TD1 137714, CIHR TD2 117588]; Genome BC; Genome Canada
[272PGX]; BC Children's Hospital Research Institute Bertram
Hoffmeister Postdoctoral Fellowship Award; Michael Smith Foundation for
Health Research Scholar Program; Indonesia Endowment Fund for Education
(LPDP) Ministry of Finance, the Republic of Indonesia
[20161022049506]; Indonesia Endowment Fund for Education (LPDP)},
 funding-text = {This research was funded by the Canadian Foundation for
Innovation/Canadian Institutes of Health Research (CIHR) (grant number
CIHR CRI-88362), the CIHR-Drug Safety and Effectiveness Network (grants
number CIHR TD1 137714 and CIHR TD2 117588), Genome BC and Genome Canada
(grant number 272PGX), the BC Children's Hospital Research Institute
Bertram Hoffmeister Postdoctoral Fellowship Award (B.I.D), Michael Smith
Foundation for Health Research Scholar Program (C.J.D.R) and Indonesia
Endowment Fund for Education (LPDP) Ministry of Finance, the Republic of
Indonesia (as a part of ZZ's Ph.D. project, grant no. 20161022049506).
The APC was funded by Indonesia Endowment Fund for Education (LPDP).},
 journal = {GENES},
 journal-iso = {Genes},
 keywords = {pharmacogenetics; cisplatin; nephrotoxicity; kidney injury; genetic
polymorphisms},
 keywords-plus = {ORGANIC CATION TRANSPORTER-2; PHARMACOGENETIC ANALYSES; DNA-REPAIR;
CHEMOTHERAPY; PLATINUM; MECHANISMS; TOXICITY; ADENOCARCINOMA;
ASSOCIATION; EXPRESSION},
 language = {English},
 month = {MAY},
 number = {5},
 number-of-cited-references = {52},
 oa = {Green Published, gold, Green Submitted},
 orcid-numbers = {Otten, Leila/0000-0002-1225-4740
Medeiros, Mara/0000-0002-6848-8933
Zazuli, Zulfan/0000-0002-1264-9558
Ross, Colin/0000-0003-1476-7037
Maitland-van der Zee, Anke/0000-0002-0414-3442
Carleton, Bruce/0000-0002-4485-4054
Liu, Geoffrey/0000-0002-2603-7296
Bedard, Philippe/0000-0002-6771-2999
Vijverberg, Susanne/0000-0002-4579-4081},
 publisher = {MDPI},
 research-areas = {Genetics & Heredity},
 researcherid-numbers = {Otten, Leila/AAY-9495-2020
Medeiros, Mara/AAK-5249-2020
Kitchlu, Abhijat/T-7314-2019
Zazuli, Zulfan/AAF-8932-2019
Kitchlu, Abhijat/AFQ-8922-2022
Maitland-van der Zee, Anke/I-9572-2016
},
 times-cited = {15},
 title = {Outcome Definition Influences the Relationship between Genetic
Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in
Adult Testicular Cancer Patients},
 type = {Article},
 unique-id = {WOS:000470964100043},
 usage-count-last-180-days = {0},
 usage-count-since-2013 = {2},
 volume = {10},
 web-of-science-categories = {Genetics & Heredity},
 web-of-science-index = {Science Citation Index Expanded (SCI-EXPANDED)},
 year = {2019}
}

